Cargando…
Examination of Diagnostic Accuracy of UroVysion Fluorescence In Situ Hybridization for Bladder Cancer in a Single Community of Japanese Hospital Patients
OBJECTIVE: UroVysion (Abbott Molecular, Inc., Illinois, USA) is based on multicolor fluorescence in situ hybridization (FISH). It has been used successfully in the USA following its Food and Drug Administration approval in 2001. However, the technology was not approved for use in Japan until 2017. C...
Autores principales: | Nagai, Takashi, Okamura, Takehiko, Yanase, Takahiro, Chaya, Ryosuke, Moritoki, Yoshinobu, Kobayashi, Daichi, Akita, Hidetoshi, Yasui, Takahiro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
West Asia Organization for Cancer Prevention
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6948889/ https://www.ncbi.nlm.nih.gov/pubmed/31030505 http://dx.doi.org/10.31557/APJCP.2019.20.4.1271 |
Ejemplares similares
-
UroVysion fluorescence in situ hybridization in urothelial carcinoma: a narrative review and future perspectives
por: Nagai, Takashi, et al.
Publicado: (2021) -
Evaluation of UroVysion for Urachal Carcinoma Detection
por: Hu, Zhiquan, et al.
Publicado: (2020) -
UroVysion fluorescence in situ hybridization (UroVysion FISH) assay for detection of bladder cancer in voided urine of Turkish patients: a preliminary study
por: Dodurga, Yavuz, et al.
Publicado: (2013) -
Refined pancreatobiliary UroVysion criteria and an approach for further optimization
por: Mettman, Daniel, et al.
Publicado: (2021) -
Initial treatment outcome and feasibility of low-dose cabazitaxel against
docetaxel- and castration-resistant prostate cancer in a Japanese hospital
por: Chaya, Ryosuke, et al.
Publicado: (2020)